The Lee Company Inc. acquires TTP Ventus Limited
WESTBROOK, Connecticut (USA) - The Lee Company is pleased to announce that it has acquired TTP Ventus Limited from TTP Group.
New Certified Climate Change Training
In conjunction with The Carbon Literacy project we are offering individuals from all sectors the opportunity to be certified as Carbon Literate by attending our course on 7 November 2022.
More about prenatal Physical Activity
A supervised prenatal Physical Activity can be started after the 3rd month and after a medical check-up.
Results from EBCam's Employee Benefits and Rewards Survey released
Local employee benefit specialists and financial advisers EBCam Ltd share the results from their first annual employee benefit and reward survey. EBCam launched an employee benefits and rewards survey earlier this year and invited local businesses to take part to aid them in benchmarking their rewards and benefits. Now, having closed the survey last month, EBCam has shared this years’ results…
CIIPM Training - new autumn training courses
CIIPM returns to in-person training for 4 half-day courses in IP&Commercialisation and Freedom to Operate searching
H.E.L Group strengthens leadership team to focus on new product development and enhanced customer support
Alan Lockley joins as Director of Global Services, Edward Quinn as Director of Product Development and Mark Appleton takes new role as Director of Research.
PhoreMost enters multi-project drug target discovery collaboration with Roche
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes.
Avacta announces AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.
Guardtech going for gold at four awards evenings in space of four months
The cleanroom construction Group are up for five honours at glitzy showpieces in London and Cambridgeshire.
Global Access Diagnostics acquires manufacturing rights for IT-LEISH rapid diagnostic test from Bio-Rad Laboratories
Bedford, UK - Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics and driving local manufacturing, announces it has acquired the manufacturing rights for the IT-LEISH rapid diagnostic test (RDT) for visceral leishmaniasis (VL) from Bio-Rad, a global leader in life science research and clinical diagnostic products.
Why isn’t Adaptability more of a priority?
Well, when I put that question to the talented members of the Scottish Institute for Business Leaders this week, their wide-ranging and insightful answers included a clutch of stand-out insights:
What are best practices from other MedTech startups? The case of Bilihome
Partnering with F.INSTITUTE, Bilihome successfully attracted investors and created realistic financial scenarios for its development, certification, and product launch phases. F.INSTITUTE supports Bilihome’s financial services, including accounting, financial modeling, and the role of CFO, payroll administration, and partially subsidy advisor.
Oxford Innovation Space appoints Gary Jennings as new Innovation Director at The Epicentre, Haverhill
Oxford Innovation Space has appointed Gary Jennings as the new Innovation Director at The EpiCentre in Haverhill alongside Centre Manager, Andrew Bell.
Avacta announces Phase I clinical study of AVA6000 to advance to the fourth cohort
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients following a positive review of the safety and tolerability data from the…
High-flying Guardtech prepare for string of international exhibitions
The cleanroom construction kings and queens are set for shows in Ireland, Germany and Singapore.
Hardware verification: are you meeting all your requirements?
Hardware verification provides evidence that a production representative sample of your medical device meets the issued hardware requirements. Unlike during software verification, which requires verification activities throughout the development, formal hardware verification is performed entirely at the end of the design process, although much of the preparation must occur earlier in the project.
Government is running out of time to support businesses in urgent need
The British Chambers of Commerce (BCC) has written to the Prime Minister, Chancellor of the Exchequer and both leadership candidates for the Conservative Party proposing a comprehensive five-point plan to provide vital support to UK businesses.
Bio-Rad introduces anti-evolocumab antibodies for use in preclinical and clinical drug development
HERCULES, Calif. — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, introduces a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha®) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. These sequence…
Can medical devices be discriminatory?
The UK government has recently called for evidence of discrimination in medical devices. The aim is to identify how devices and technologies may be biased against different genders, ethnicities and other socio-demographic groups. This begs the question – can medical devices be designed to discriminate against certain users? The short answer is yes – but not intentionally. While it is, of…
Solving your drug delivery needs at PDA
Brennan Miles, John Burke, Chris Hurlstone and Alastair Willoughby from Team Consulting will be attending the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices Conference, live in Palm Springs from 18th-19th October.
Can you do too much system engineering?
These days, a medical device needs to be considered as one element of a connected whole. Systems engineering has become a crucial part of medical device development, but can you do too much of it? Our Head of Electronics Engineering, Peter Matthewson, discusses in a new blog post.
Delivering the most viscous drug ever put in an autoinjector
Autoinjectors offer patients a smart way to get their medication. Some drugs however can be too viscous for this type of delivery. Find out how Springboard helped a client solve the tricky problem of administering a highly viscous drug via and autoinjector, helping patients around the world to access their medication.
Computational chemistry news 2022
Computational chemistry news from Cresset, including: custom force fields, molecular dynamics, molecular scaffolds, clustering algorithms in Spark, Cresset Discovery, small molecule design.
Evonetix commences early access program for DNA synthesised by thermal control on its semiconductor chip
Cambridge, UK - Evonetix, the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix’s DNA synthesis capability brings together patented semiconductor chip design and proprietary, thermally controlled synthesis chemistry, which will be integral to the Company’s future gene…